Novo Nordisk (NOVO) AGM 2023 summary

Opening remarks and agenda

• Chair Helge Lund highlighted 2022 progress on strategic aspirations and the reach of almost 40 million patients, a record.

• The AGM was held partially electronically, allowing participation in person or virtually; shareholders were encouraged to submit proxies or votes in advance.

Financial performance review

• 2022 performance was described as strong, with continued progress on strategic aspirations and almost 40 million patients reached globally, the most ever.

Board and executive committee updates

• Helge Lund and Henrik Poulsen were re-elected as Board chair and vice chair; Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, Kasim Kutay and Martin Mackay were re-elected as Board members.

• Committee appointments included Debroux as Audit Committee chair, Martin Mackay as Research & Development Committee chair, and Helge Lund as Nomination Committee chair.

• Deloitte Statsautoriseret Revisionspartnerselskab was re-appointed as auditor.